162 related articles for article (PubMed ID: 28728751)
1. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Chan JK; Deng W; Higgins RV; Tewari KS; Bonebrake AJ; Hicks M; Gaillard S; Ramirez PT; Chafe W; Monk BJ; Aghajanian C
Gynecol Oncol; 2017 Sep; 146(3):554-559. PubMed ID: 28728751
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Powell MA; Sill MW; Goodfellow PJ; Benbrook DM; Lankes HA; Leslie KK; Jeske Y; Mannel RS; Spillman MA; Lee PS; Hoffman JS; McMeekin DS; Pollock PM
Gynecol Oncol; 2014 Oct; 135(1):38-43. PubMed ID: 25019571
[TBL] [Abstract][Full Text] [Related]
3. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Finn RS; Kang YK; Mulcahy M; Polite BN; Lim HY; Walters I; Baudelet C; Manekas D; Park JW
Clin Cancer Res; 2012 Apr; 18(7):2090-8. PubMed ID: 22238246
[TBL] [Abstract][Full Text] [Related]
4. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
McCourt CK; Deng W; Dizon DS; Lankes HA; Birrer MJ; Lomme MM; Powell MA; Kendrick JE; Saltzman JN; Warshal D; Tenney ME; Kushner DM; Aghajanian C
Gynecol Oncol; 2017 Jan; 144(1):101-106. PubMed ID: 28029447
[TBL] [Abstract][Full Text] [Related]
5. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Park JW; Finn RS; Kim JS; Karwal M; Li RK; Ismail F; Thomas M; Harris R; Baudelet C; Walters I; Raoul JL
Clin Cancer Res; 2011 Apr; 17(7):1973-83. PubMed ID: 21349999
[TBL] [Abstract][Full Text] [Related]
6. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.
Kudo M; Han G; Finn RS; Poon RT; Blanc JF; Yan L; Yang J; Lu L; Tak WY; Yu X; Lee JH; Lin SM; Wu C; Tanwandee T; Shao G; Walters IB; Dela Cruz C; Poulart V; Wang JH
Hepatology; 2014 Nov; 60(5):1697-707. PubMed ID: 24996197
[TBL] [Abstract][Full Text] [Related]
7. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Bender D; Sill MW; Lankes HA; Reyes HD; Darus CJ; Delmore JE; Rotmensch J; Gray HJ; Mannel RS; Schilder JM; Hunter MI; McCourt CK; Samuelson MI; Leslie KK
Gynecol Oncol; 2015 Sep; 138(3):507-12. PubMed ID: 26186911
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Santin AD; Sill MW; McMeekin DS; Leitao MM; Brown J; Sutton GP; Van Le L; Griffin P; Boardman CH
Gynecol Oncol; 2011 Sep; 122(3):495-500. PubMed ID: 21684583
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML
Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040
[TBL] [Abstract][Full Text] [Related]
10. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Monk BJ; Sill MW; Burger RA; Gray HJ; Buekers TE; Roman LD
J Clin Oncol; 2009 Mar; 27(7):1069-74. PubMed ID: 19139430
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Kunos C; Deng W; Dawson D; Lea JS; Zanotti KM; Gray HJ; Bender DP; Guaglianone PP; Carter JS; Moore KN
Int J Gynecol Cancer; 2015 Mar; 25(3):484-92. PubMed ID: 25594147
[TBL] [Abstract][Full Text] [Related]
13. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
[TBL] [Abstract][Full Text] [Related]
14. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Jones RL; Ratain MJ; O'Dwyer PJ; Siu LL; Jassem J; Medioni J; DeJonge M; Rudin C; Sawyer M; Khayat D; Awada A; de Vos-Geelen JMPGM; Evans TRJ; Obel J; Brockstein B; DeGreve J; Baurain JF; Maki R; D'Adamo D; Dickson M; Undevia S; Geary D; Janisch L; Bedard PL; Abdul Razak AR; Kristeleit R; Vitfell-Rasmussen J; Walters I; Kaye SB; Schwartz G
Eur J Cancer; 2019 Oct; 120():132-139. PubMed ID: 31522033
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
17. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Modesitt SC; Sill M; Hoffman JS; Bender DP;
Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
